High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

By sjmartinez • April 29, 2025

Riddler SA, Moodie Z, Clark J, Yen C, Allen M, Furch BD, Lu H, Grant S, Mondal K, Anderson M, Maenza J, Lemos MP, Woodward Davis AS, Walsh SR, Sobieszczyk ME, Frank I, Goepfert P, Stephenson KE, Baden LR, Tieu HV, Keefer MC, McElrath MJ, Kublin JG, Corey L. High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). Ann Intern Med. 2025 Apr 29. doi: 10.7326/ANNALS-24-02701. Epub ahead of print. PMID: 40294415.

Tags: Infectious Diseases, Publications

Prevalence, characteristics, and clinical course of mpox-related ophthalmic disease (MBOTE-EYE): a prospective cohort study in South Kivu, Democratic Republic of the Congo

Kabesha T, Van Dijck C, Mudwanga S, Houben S, Mujula Y, Munganga P, Tshomba JC, Mukari G, Wawina-Bokalanga T, Kinganda-Lusamaki E, Jacobs BK, Tsoumanis A,[...]

Determinants of PrEP Delivery Platform Choice in Adolescents and Young People: The Fast-PrEP Project in Cape Town, South Africa

Rousseau E, Bondarchuk C, Lebelo K, Matsebula L, Bennin F, Macdonald P, Pike C, Vanto O, Mathole N, Fynn L, Davey DJ, Coakley C, Wallace[...]

Proteomic Immune Signatures of Severe HIV-Associated Tuberculosis in Sub-Saharan Africa: A Prospective, Multicenter Analysis From Uganda

Ross JE, Tomoiaga AS, Owor N, Lu X, Shinyale J, Kiyingi T, Asasira I, Eliku PJ, Nsubuga JB, Nsereko C, Nayiga I, Kyebambe S, Ochar[...]